Technology IPO of the Tübingen biotech company Curevac expected

07:40  14 august  2020
07:40  14 august  2020 Source:   finanzen.net

At Crèvecoeur-le-Grand, she launched her loose tea business

 At Crèvecoeur-le-Grand, she launched her loose tea business © DR At 24, Loredana Habsiger started her business selling bulk tea. Tea, she drinks liters. But Loredana Habsiger was “fed up” with going to the supermarket to get it. And then, to buy large quantities, you had to go to Beauvais, in the nearest Biocoop. “When you don't live in a big city, it's more complicated to get supplies. So each time, my friends asked me to bring them back, ”she says.

A CureVac IPO is on investors’ minds after the company filed to go public . CureVac ’s current project is a coronavirus vaccine. It’s a leading biotech company based in Tübingen , Germany. The company uses messenger RNA (mRNA) technology . It helps develop cancer therapies and

German biotech firm CureVac is to become the second company in Germany to begin human trials of an experimental coronavirus vaccine, the The company , based in Tübingen in the southwestern state of Baden-Württemberg, said it expects the first meaningful results from phase one of the trial by

Curevac ist bei der Suche nach einem Impfstoff gegen Sars-CoV-2 einer von mehreren Hoffnungsträgern weltweit. © Sebastian Gollnow / dpa Curevac is one of several hopes worldwide in the search for a vaccine against Sars-CoV-2.

The Tübingen-based biotech company Curevac is starting the New York Stock Exchange to raise money for the development of its corona vaccine. Around 150 million dollars (almost 130 million euros) are estimated from the proceeds.

According to the prospectus, the short-term production capacity will be expanded with a further 50 million dollars. The main investor of Curevac, SAP co-founder Dietmar Hopp, will retain control after the IPO. When looking for a vaccine against Sars-CoV-2,

Curevac is one of several bearers of hope worldwide - and not the only one who is raising fresh money on the stock market for it. On Thursday, the shares of the Chinese company Cansino, already listed in Hong Kong, also started in Shanghai - and the price doubled at times.

Tesla Has Been Working On an RNA Bioreactor

  Tesla Has Been Working On an RNA Bioreactor The technology could eventually advance a COVID-19 vaccine.CureVac has made the news recently because of a misinformed factoid that it was being purchased by President Donald Trump. That’s partly because CureVac is working on the groundwork for a COVID-19 (coronavirus) vaccine. Today, the European Investment Bank (EIB) reported that it's awarded an $84 million loan to CureVac to accelerate that vaccine development process.

CureVac , Tübingen , Germany. 5,548 likes · 278 talking about this. CureVac is a leading clinical stage biotechnology company in the field of The German Federal Government has decided to invest 300 million Euros in CureVac as part of the Corona Economic Stimulus and Future Technologies Package.

CureVac - the RNA people, Tübingen , Germany. 466 likes · 26 talking about this. CureVac is a leading clinical stage biotechnology company in the field of

Curevac's IPO on the Nasdaq technology exchange is expected to bring in around $ 245 million. Hopp also wants to buy shares for $ 100 million.

After the share placement, Hopp's Dievini company, which was previously the majority owner, will hold almost 50 percent of the shares. The stately promotional bank KfW then comes to just under 17 percent and the pharmaceutical company GlaxoSmithKline to a good 8 percent.

In a recently completed financing round, Curevac had already raised around 560 million euros from investors. Among them was the federal government, which announced KfW's investment for 300 million euros in June. The aim was therefore also to prevent a possible takeover from abroad in the race for a corona vaccine. According to the federal government, the initiative came from the company. The Qatar sovereign wealth fund and GlaxoSmithKline also appeared as investors. The British company is one of the leading vaccine groups in Europe.

At the beginning of March, US President Donald Trump invited then Curevac boss Dan Menichella and other pharmaceutical representatives to the White House to find out more about the vaccine search. Shortly thereafter there was a stir about the Baden-Württemberg company: According to media reports, Trump tried to secure the vaccine exclusively for his country and offered a large amount for it, which caused outrage. However, Hopp vehemently rejected both a sale and an exclusive production for Trump. Then the federal government got involved.

Missile launch or storm repairs? Flurry of activity fuels speculation of North Korea test .
Analysts and security officials say they are watching for signs that North Korea may use an upcoming holiday to unveil new weapons or test fire a submarine-launched ballistic missile (SLBM), after a flurry of activity was detected at a key base. © Reuters/MAXAR TECHNOLOGIES A satellite image shows an overview of people assembled in formation near Kim Il Sung Square and rehearsing for the upcoming military parade of the 75th Anniversary of the Workers' Party of North Korea in Pyongyang, North Korea Formations of troops have been seen practicing for what is expected to be a major military parade on Oct.

—   Share news in the SOC. Networks
usr: 1
This is interesting!